We apply our deep understanding of both markets and the science and business of drug development to create effective corporate communications strategies and deliver results. Trophic’s offerings cover all aspects of strategic communications for pharmaceutical and biotech companies including positioning, industry visibility and perception, public and media relations, investor relations and senior counsel.
What we do?
PUBLIC RELATIONS
The key to good public relations lies in identifying the unique traits and goals of each company and building a strategy that emphasizes and cultivates these elements. Through the development of a targeted messaging strategy, we want to support your company in solidifying its position and sharing its own story in the industry. Our public relations services include:
- Corporate Positioning & messaging development
- Press Releases
- Media Outreach
- Interview coordination & preparation
- Social media strategy & support
- Conference and Scientific meeting support
- Scientific Communications
- Event planning, i.e., scientific symposia, webinars, KOL day, etc.
- Patient advocacy
- Crisis communications
INVESTOR RELATIONS
Navigating and managing investor relations is a critical element to each company regardless of size or industry. At Trophic, we build our investor relations strategy based on research and one-on-one discussions with the financial community to ensure the best outcome for our clients. Our investor relations services include:
- Financial communications, i.e quarterly and annual reports, conference call scripts, etc.
- Run-up to IPO
- Perception audits
- Peer analysis
- Corporate presentation training
- Roadshow planning and onsite support
- Investor and analyst days
- Financial conference support
MATERIALS SUPPORT
From corporate websites to comprehensive Q&As, we can offer your firm a range of materials to support you in your messaging and strategy. Our materials services include:
- Website creation and updates
- Logo and brand development
- Corporate presentation development and updates
- Corporate Q&As
- Media and investor backgrounders